PlainRecalls
FDA Drug Moderate Class II Terminated

Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05

Reported: February 2, 2022 Initiated: December 29, 2021 #D-0450-2022

Product Description

Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05

Reason for Recall

Superpotent and Failed Tablet/Capsule Specifications

Details

Recalling Firm
Aurobindo Pharma USA Inc.
Units Affected
792 bottles
Distribution
Nationwide in the US
Location
East Windsor, NJ

Frequently Asked Questions

What product was recalled?
Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05. Recalled by Aurobindo Pharma USA Inc.. Units affected: 792 bottles.
Why was this product recalled?
Superpotent and Failed Tablet/Capsule Specifications
Which agency issued this recall?
This recall was issued by the FDA Drug on February 2, 2022. Severity: Moderate. Recall number: D-0450-2022.